Wells Fargo
MRSN

Wells Fargo’s Mersana Therapeutics MRSN Stock Holding History

Wells Fargo’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,272
Closed -$43K – 6680
2020
Q2 		$43K Buy
+1,272
New +$434K ﹤0.01% 5530

Other funds holding MRSN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo's MRSN Position: Q1 2026 in Review

Wells Fargo sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 40 shares — an estimated $1.16K sold.

Wells Fargo first reported a position in MRSN in Q3 2017 and held it in 33 quarters. The position peaked at $3.27M in Q4 2020. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.

  • Wells Fargo reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Wells Fargo sold 40 Mersana Therapeutics shares in Q1 2026, an estimated $1.16K.
  • Wells Fargo first reported a position in Mersana Therapeutics in Q3 2017 and held it in 33 quarters.
  • Wells Fargo's Mersana Therapeutics position peaked at $3.27M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.